Reappraisal and perspectives of clinical drug–drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus

Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models

(2016) Manthena V. Varma et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Absence of Drug–Drug Interactions Between Luseogliflozin, a Sodium–Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males

(2015) Takashi Sasaki et al.   ADVANCES IN THERAPY

Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review

(2015) Shashank R Joshi et al.   EXPERT OPINION ON PHARMACOTHERAPY

Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. “The MASTER randomized, controlled trial”

(2014) Atsushi Mikada et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination

(2014) Yuri Ono et al.   EXPERT OPINION ON PHARMACOTHERAPY

Efficacy of voglibose in type 2 diabetes

(2014) Kohei Kaku   EXPERT OPINION ON PHARMACOTHERAPY

The effect of voglibose on the pharmacokinetics of metformin in healthy Korean subjects

(2014) Ho-Sook Kim et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects

(2014) S. Kim et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Simultaneous Quantification of Aliskiren, Valsartan and Sitagliptin by LC with Fluorescence Detection: Evidence of Pharmacokinetic Interaction in Rats

(2013) Vishal Goyani et al.   CHROMATOGRAPHIA

Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes

(2013) Masayuki Yamaguchi et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes

(2013) Akira Imamura et al.   Diabetes Therapy

Transporter-Mediated Drug–Drug Interactions with Oral Antidiabetic Drugs

(2011) Sabine Klatt et al.   Pharmaceutics

Reduction of the acute bioavailability of metformin by the α-glucosidase inhibitor acarbose in normal man

(2010) A. J. SCHEEN et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions

(2009) Andreas Holstein et al.   Expert Opinion on Drug Metabolism & Toxicology

The Drug Transporter−Metabolism Alliance: Uncovering and Defining the Interplay

(2009) Leslie Z. Benet   MOLECULAR PHARMACEUTICS

Interplay of Transporters and Enzymes in Drug and Metabolite Processing

(2009) K. Sandy Pang et al.   MOLECULAR PHARMACEUTICS

Prediction of pharmacokinetic drug–drug interaction caused by changes in cytochrome P450 activity using in vivo information

(2009) Akihiro Hisaka et al.   PHARMACOLOGY & THERAPEUTICS